Abraxis Bioscience, Inc. (NASDAQ: ABBI) is a strategically integrated pharmaceutical company that manufactures, markets and develops injectable products, with a focus on oncology and anti-infectives. Acquired by Celgene.

Achillion Pharmaceuticals (NASDAQ: ACHN) is developing iron nanoparticle-based therapeutics. The company’s lead product, Feraheme, has been approved by the FDA for the treatment of iron deficiency anemia in adult patients with chronic kidney disease.

Acura Pharmaceuticals is a specialty pharmaceutical company engaged in research, development and manufacture of innovative Aversion® (abuse deterrent) Technology and related product candidates. Acura’s lead product, Oxecta, has been approved by the FDA and is partnered with Pfizer.

AMAG Pharmaceuticals (NASDAQ: AMAG) is developing iron nanoparticle-based therapeutics. The company’s lead product, Feraheme, has been approved by the FDA for the treatment of iron deficiency anemia in adult patients with chronic kidney disease.

Aspreva Pharmaceuticals (NASDAQ: ASPV) is a pharmaceutical company which identifies, develops and commercializes new applications for existing medicines. Acquired by Galenica.

Avanir Pharmaceuticals (NASDAQ: AVNR) is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases. The company's lead product, Nuedexta, has been approved by the FDA for the treatment of pseudobulbar affect.

Biodel, Inc. is a biopharmaceutical drug delivery company with novel products in development for the treatment of diabetes.

BioForm Medical, Inc. is developing and commercializing Radiesse and Coaptite, proprietary gels containing calcium hydroxylapatite, for cosmetic applications, stress urinary incontinence (SUI), vocal cord insufficiency and paralysis (VFI), and other disorders. Acquired by Merz.

Chelsea Therapeutics (NASDAQ: CHTP) acquires, develops and commercializes innovative products for the treatment of important unmet medical needs such as rheumatoid arthritis, psoriasis, and other inflammatory conditions.

CoTherix (NASDAQ: CTRX) is marketing Ventavis® (iloprost aerosol) for the treatment of primary pulmonary hypertension, an orphan indication, for the U.S. market. Acquired by Actelion.

Hamilton Pharmaceuticals, Inc. (HPI) is developing novel treatments for central nervous system disease. Acquired by Neuren.

InterMune (NASDAQ: ITMN) is a biopharmaceutical company focused on the applied research, development and marketing of life-saving therapies for pulmonary diseases.

Prestwick Pharmaceuticals is a specialty pharmaceutical company engaged in the development and marketing of drugs for diseases of the CNS. Acquired by Biovail.

Transcept Pharmaceuticals is developing products that utilize the company's proprietary drug delivery system. The company’s lead product, Intermezzo, has been approved by the FDA and is partnered with Purdue Pharma.

Vicept Therapeutics is developing novel products for the treatment of rosacea and other dermatological conditions. Acquired by Allergan.